JP2018512402A5 - - Google Patents

Download PDF

Info

Publication number
JP2018512402A5
JP2018512402A5 JP2017548142A JP2017548142A JP2018512402A5 JP 2018512402 A5 JP2018512402 A5 JP 2018512402A5 JP 2017548142 A JP2017548142 A JP 2017548142A JP 2017548142 A JP2017548142 A JP 2017548142A JP 2018512402 A5 JP2018512402 A5 JP 2018512402A5
Authority
JP
Japan
Prior art keywords
immunoconjugate
immune complex
subject
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017548142A
Other languages
English (en)
Japanese (ja)
Other versions
JP6847846B2 (ja
JP2018512402A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/022085 external-priority patent/WO2016145354A1/en
Publication of JP2018512402A publication Critical patent/JP2018512402A/ja
Publication of JP2018512402A5 publication Critical patent/JP2018512402A5/ja
Application granted granted Critical
Publication of JP6847846B2 publication Critical patent/JP6847846B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017548142A 2015-03-12 2016-03-11 Epcam陽性膀胱癌を標的とする投薬戦略 Expired - Fee Related JP6847846B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562132251P 2015-03-12 2015-03-12
US62/132,251 2015-03-12
US201562267386P 2015-12-15 2015-12-15
US62/267,386 2015-12-15
PCT/US2016/022085 WO2016145354A1 (en) 2015-03-12 2016-03-11 Dosing strategies for targeting epcam positive bladder cancer

Publications (3)

Publication Number Publication Date
JP2018512402A JP2018512402A (ja) 2018-05-17
JP2018512402A5 true JP2018512402A5 (cg-RX-API-DMAC7.html) 2019-04-18
JP6847846B2 JP6847846B2 (ja) 2021-03-24

Family

ID=56879327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017548142A Expired - Fee Related JP6847846B2 (ja) 2015-03-12 2016-03-11 Epcam陽性膀胱癌を標的とする投薬戦略

Country Status (8)

Country Link
US (1) US10583198B2 (cg-RX-API-DMAC7.html)
EP (1) EP3268041A4 (cg-RX-API-DMAC7.html)
JP (1) JP6847846B2 (cg-RX-API-DMAC7.html)
CN (1) CN107580501A (cg-RX-API-DMAC7.html)
AU (1) AU2016228760B2 (cg-RX-API-DMAC7.html)
CA (1) CA2979400A1 (cg-RX-API-DMAC7.html)
HK (1) HK1249731A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016145354A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2826735C (en) 2003-04-30 2019-06-04 University Of Zurich Methods for treating cancer using an immunotoxin
PL3052525T3 (pl) 2013-10-02 2020-03-31 Viventia Bio Inc. Przeciwciała anty- EpCAM i sposoby wykorzystania
JP6847846B2 (ja) 2015-03-12 2021-03-24 セセン バイオ,インコーポレイテッド Epcam陽性膀胱癌を標的とする投薬戦略
CA2979394A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer
EP3426271B1 (en) 2016-03-10 2025-08-27 CG Oncology, Inc. Methods of treating solid tumors by combination therapy
AU2018251987B2 (en) * 2017-04-14 2024-11-28 Cg Oncology, Inc. Methods of treating bladder cancer
WO2023222024A1 (en) * 2022-05-18 2023-11-23 Bj Bioscience Inc. Bispecific antibodies targeting epcam and cd3
CN115109164A (zh) * 2022-06-07 2022-09-27 博际生物医药科技(杭州)有限公司 靶向epcam和cd3的双特异性抗体

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
IL98528A0 (en) 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
GB9709421D0 (en) 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
WO1998055623A1 (en) 1997-06-06 1998-12-10 Tanox Pharma B.V. Type-1 ribosome-inactivating protein
EP1489100B1 (en) 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US6280742B1 (en) 1998-06-17 2001-08-28 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
CA2369622C (en) 1999-04-09 2011-06-14 Universitat Zurich Novel method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CA2446087C (en) 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
US20030148950A1 (en) 2001-10-09 2003-08-07 Li Xin Kringle domain 1 of human hepatocyte growth factor and uses therefor
PL374495A1 (en) 2001-10-15 2005-10-31 Immunomedics, Inc. Direct targeting binding proteins
US20040022726A1 (en) 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
SI21272A (sl) 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Sintetski gen za humani granulocitne kolonije stimulirajoči dejavnik za ekspresijo v E. coli
CA2424255A1 (en) 2003-03-26 2004-09-26 Claudio Di Paolo Immunotoxins
CA2826735C (en) * 2003-04-30 2019-06-04 University Of Zurich Methods for treating cancer using an immunotoxin
DK1737961T3 (da) 2004-03-19 2013-08-05 Merck Patent Gmbh Modificerede bouganin proteiner, cytotoxiner og fremgangsmåder og anvendelser deraf
EP2927322A1 (en) 2004-06-10 2015-10-07 Viventia Bio Inc. Tumor specific antibody
US20090171317A1 (en) 2006-03-10 2009-07-02 Ebrahim Versi Self-Catheterization Device To Administes Compounds To The Bladder
CA2668017A1 (en) 2006-10-30 2008-05-08 Viventia Biotech Inc. Improved conjugates
US8263744B2 (en) 2007-04-19 2012-09-11 Viventia Biotechnologies Inc. Binding proteins that bind to EpCAM linked to an effector molecule
CA2700815A1 (en) 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
CA2618163A1 (en) 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers
MX2011010469A (es) 2009-04-08 2012-03-14 Deutsches Krebsforsch Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer.
GB0909904D0 (en) 2009-06-09 2009-07-22 Affitech As Product
WO2011116387A1 (en) 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates
EP2723393A4 (en) 2011-06-24 2015-02-25 Ct Se Llc EXTRACELLULAR TARGETED CONSTITUENT CONJUGATES
KR20160006697A (ko) 2013-04-12 2016-01-19 비벤티아 바이오 인코포레이티드 간세포 암종을 검출 및 치료하기 위한 조성물 및 방법
PL3052525T3 (pl) 2013-10-02 2020-03-31 Viventia Bio Inc. Przeciwciała anty- EpCAM i sposoby wykorzystania
JP6847846B2 (ja) 2015-03-12 2021-03-24 セセン バイオ,インコーポレイテッド Epcam陽性膀胱癌を標的とする投薬戦略
CA2979394A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer
WO2017040801A2 (en) 2015-09-02 2017-03-09 Viventia Bio Inc. Methods for making and using an immunoconjugate for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2018512402A5 (cg-RX-API-DMAC7.html)
JP2016528247A5 (cg-RX-API-DMAC7.html)
JP2014158469A5 (cg-RX-API-DMAC7.html)
JP2018518454A5 (cg-RX-API-DMAC7.html)
JP2016520082A5 (cg-RX-API-DMAC7.html)
JP2017506217A5 (cg-RX-API-DMAC7.html)
JP2016094424A5 (cg-RX-API-DMAC7.html)
JP2019519499A5 (cg-RX-API-DMAC7.html)
RU2019106663A (ru) Комбинированная терапия рака
JP2020508317A5 (cg-RX-API-DMAC7.html)
JP2012501626A5 (cg-RX-API-DMAC7.html)
JP2013520442A5 (cg-RX-API-DMAC7.html)
JP2009533367A5 (cg-RX-API-DMAC7.html)
JP2018505177A5 (cg-RX-API-DMAC7.html)
JP2011506483A5 (cg-RX-API-DMAC7.html)
JP2015534579A5 (cg-RX-API-DMAC7.html)
JP2017501167A5 (cg-RX-API-DMAC7.html)
JP2016519650A5 (cg-RX-API-DMAC7.html)
RU2017108173A (ru) Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
JP2008528486A5 (cg-RX-API-DMAC7.html)
JP2015517529A5 (cg-RX-API-DMAC7.html)
JP2020510039A5 (cg-RX-API-DMAC7.html)
JP2018529661A5 (cg-RX-API-DMAC7.html)
WO2016090024A4 (en) Combination therapy for treatment of cancer
WO2017042352A1 (en) Dosing regimens for anti-tf-antibody drug-conjugates